

# Pneumococcal Vaccines

**Allison Kempe, MD**

**Pneumococcal Vaccines Work Group Chair**

**Advisory Committee on Immunization Practices**

**October 20, 2016**



# Pneumococcal Vaccines Work Group

## ACIP members

Arthur Reingold (Chair)

Nancy Bennett

Allison Kempe

## Ex Officio members

Lucia Lee (FDA)

Tina Mongeau (FDA)

**CDC Lead (CDC/NCIRD)**

Tamara Pilishvili

## Liaison representatives and consultants

Rick Zimmerman (AAFP)

William Schaffner (NFID)

Caroline Quach (NACI)

Mark Sawyer (AAP, PIDS)

Jane Zucker (AIM)

Monica Farley (VA)

Carol Baker (IDSA)

Kathy Neuzil (IDSA)

Sandra Fryhofer (ACP, AMA)

Keith Klugman

Lorry Rubin

Jeff Duchin

# **Pneumococcal Vaccines Work Group: Terms of Reference**

- Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines
- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence
- Revise or update recommendations for pneumococcal vaccine use, as needed

# ACIP meeting August 2014

## PCV13 recommended for adults $\geq 65$ years of age

### Work Group Conclusions

- In the short-term, a recommendation for universal PCV13 use is warranted
- In the long-term, continued herd effects may limit the utility of a universal recommendation
  - The magnitude of indirect effects unknown
  - Uncertainty around the burden of vaccine preventable non-bacteremic pneumonia
- Opportunity to prevent disease during the 2014-2015 respiratory season

## **Potential time-limited utility of routine PCV13 use among adults $\geq 65$ years**

The following statement included in 2014 ACIP vote:

The recommendations for routine PCV13 use among adults  $\geq 65$  years old should be re-evaluated in 2018 and revised as needed

## **ACIP meeting August 2014: Potential time-limited utility of routine PCV13 use among adults $\geq 65$ years**

- ❑ Monitoring of the impact of the new recommendation in the target population of adults  $\geq 65$  years old
- ❑ Continued monitoring of disease trends among PCV13-naïve adults (19-64 years old without PCV13 indications) is needed to evaluate the impact of herd effects and the long-term utility of routine PCV13 use among adults
- ❑ ACIP should be routinely updated on the changes in vaccine-preventable disease burden among adults due to PCV13 direct and indirect effects during the next 3 years
- ❑ These data should inform revisions as needed to the proposed adult PCV13 recommendations in 2018

## **Outline for Today's Pneumococcal Vaccines Session**

1) Update on direct and indirect impact of PCV13 use on invasive disease among adults and children in the US

Tamara Pilishvili

2) PCV13 impact among adults with chronic medical conditions with and without indications for PCV13 use

Sana Ahmed

3) Outline of research agenda to inform potential policy reconsideration in 2018 for PCV13 use among adults

Tamara Pilishvili

# Outline for Today's Pneumococcal Vaccines Session

## Discussion/Questions to ACIP:

- Is the proposed research agenda appropriate to help determine if potential policy change is needed in 2018?
- What additional information will the committee need to help determine in 2018 whether continued PCV13 use in adults is warranted?